
About Bavarian Nordic
Bavarian Nordic is a publicly listed company based in Kvistgard (Denmark) founded in 1994. Therapeutic vaccines for cancer and infectious diseases are developed. It operates on a Professional Services model. The company has 1,610 employees. Its website bavarian-nordic.com draws about 32 thousand monthly visits. Bavarian Nordic offers products and services including Vaccines. Its focus areas include Biotechnology and Vaccines. Its legal entity is Bavarian Nordic A/S.
Company details
Bavarian Nordic is engaged in the research, development, and manufacturing of innovative vaccines aimed at protecting public health. The company operates within the biotechnology sector, focusing on life-changing solutions to address global health challenges. Operations span across multiple international locations, ensuring a broad reach and impact through advanced vaccine technologies and dedicated resources for healthcare professionals.
- Headquarters Kvistgard, Denmark
- Employees 1,610
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phoneβ’β’β’β’ β’β’β’β’
- Website bavarian-nordic.com
- Social LinkedIn X Facebook
- Legal Name Bavarian Nordic A/S
- Annual Revenue$970.66 M (USD)8.06as on Dec 31, 2025
- Net Profit$217.1 M (USD)39.21as on Dec 31, 2025
- EBITDA$258 M (USD)4.87as on Dec 31, 2025
- Latest Funding Round$183.43M (USD), Post-IPO
Mar 2021
- Employee Count1,610
Products & Services of Bavarian Nordic
Bavarian Nordic offers a comprehensive portfolio of products and services, including Vaccines.
Innovative life-saving vaccines are developed and manufactured here.
Funding Insights of Bavarian Nordic
- Total Rounds 1
- Last Round Post-IPO β $183.43M
- First Round $183.43M
(Mar 2021)
All 1 funding rounds of Bavarian Nordic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $183.43M | Post-IPO | β | β | β |
People of Bavarian Nordic
287 people are tracked at Bavarian Nordic (95 in leadership, 10 in board & advisors, 182 in team); the tracked headcount is 1,610.
| Name | Role | Group |
|---|---|---|
Laurence De Moerlooze | EVP & Chief Medical Officer | Leadership |
Pascal Schwarz | Director, Manufacturing, Science And Technology (ms&t) | Leadership |
Tommi Kainu | Executive Vice President, Chief Business Officer | Leadership |
Adele Marthaler | Head Of Contract Manufacturing Solutions | Leadership |
Demetria B. | Human Resources Director | Leadership |
Heidi Ringer Dethlefsen | Finance Director | Leadership |
Carolin S. | Head Assay Development | Leadership |
Britt Juul Christensen | Senior Vice President Quality | Leadership |
Ken Carlo Iledan | Head Of Clinical Operations | Leadership |
Baptiste Leclerc | Manager CMO | Leadership |
Helle Thanning | Senior HR Business Partner | Leadership |
Henrik Juuel | Executive Vice President, Chief Financial Officer | Leadership |
Paul Chaplin | President & CEO | Leadership |
Jean-Christophe May | EVP & Chief Commercial Officer | Leadership |
Russell Thirsk | EVP & COO | Leadership |
Joe Kukolla | Associate Director Of Marketing | Leadership |
James G. Burns | Director, Medical Affairs, Canada | Leadership |
Alexandra S. | Vice President Commercial, Germany And Switzerland | Leadership |
Claes Axäng | Director R D And CSPV QA | Leadership |
Bernard Hoet | Vice President Of Medical Strategy At Bavarian Nordic | Leadership |
267 more people are available in the full profile.
Complete people profiles for Bavarian Nordic
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bavarian Nordic
Bavarian Nordic is a publicly listed company on the OMXCOP with ticker symbol BAVA in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jan 2000
- Listed onSTO: BAVA
- Listed entityBavarian Nordic A/S
- Exchange sectorHealth technology
- ISINDK0015998017
- Share price236.80 DKK · 2026-10-14
- Market capitalisation18,744,536,277.00 DKK
- Price to earnings11.8
- EPS (diluted, trailing year)20.00 DKK
- Volume (last session)129,652
Financials of Bavarian Nordic
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 6.17B DKK | 1.38B DKK | 1.64B DKK |
| 2024 | 5.71B DKK | 988.0M DKK | 1.56B DKK |
| 2023 | 7.06B DKK | 1.48B DKK | 2.05B DKK |
| 2022 | 3.15B DKK | -347.4M DKK | 328.5M DKK |
| 2021 | 1.89B DKK | -464.8M DKK | 67.7M DKK |
Detailed financial statements for Bavarian Nordic
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Bavarian Nordic
3 dated milestones of Bavarian Nordic across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Bavarian Nordic is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $183.4M.
Web traffic of Bavarian Nordic
The website of Bavarian Nordic (bavarian-nordic.com) receives about 31.7K visits a month and ranks #762,962 among all websites worldwide, #892 in Biotechnology and Pharmaceuticals.
- Monthly visits31.7K
▼ 20.8% vs previous month
- Unique visitors14.1K
per month
- Global rank#762,962
among all websites
- Category rank#892
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit2.2
- Average visit54 sec
- DevicesDesktop 42% Β· Mobile 58%
Websites whose visitors overlap most with Bavarian Nordic. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lundbeck.com | 100% | 137.6K | #280,857 | View details | |
| vical.com | 100% | View details | |||
| crucell.com | 93% | View details | |||
gskvaccines.com | gskvaccines.com | 88% | β | ||
arthurdovermd.com | arthurdovermd.com | 86% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Bavarian Nordic
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bavarian Nordic
Complete news archive for Bavarian Nordic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bavarian Nordic
Bavarian Nordic was founded in 1994 and raised its 1st funding round 27 years after it was founded.
Bavarian Nordic is headquartered in Kvistgard, Denmark.
Bavarian Nordic has 1,610 employees.
Annual revenue of Bavarian Nordic is $970.66M as on Dec 31, 2025.
Bavarian Nordic is engaged in the research, development, and manufacturing of innovative vaccines aimed at protecting public health. The company operates within the biotechnology sector, focusing on life-changing solutions to address global health challenges. Operations span across multiple international locations, ensuring a broad reach and impact through advanced vaccine technologies and dedicated resources for healthcare professionals.
Bavarian Nordic offers Vaccines.
Yes, Bavarian Nordic is publicly traded on OMXCOP under the ticker symbol BAVA.
Bavarian Nordic operates through Bavarian Nordic A/S.
